Your browser doesn't support javascript.
loading
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
Dong, Yanling; Wang, Shuang; Cong, Lin; Zhang, Ting; Cheng, Jun; Yang, Nannan; Qu, Xiaohong; Li, Dongfang; Zhou, Xueying; Wang, Holly; Lee, Michael; Wang, Meng; Chen, Stephen; Ousler, George W; Chen, Xiaoxiang; Xie, Lixin.
Afiliação
  • Dong Y; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Wang S; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Cong L; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Zhang T; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Cheng J; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Yang N; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Qu X; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Li D; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China.
  • Zhou X; Harbour BioMed, Shanghai, China.
  • Wang H; Harbour BioMed, Shanghai, China.
  • Lee M; Harbour BioMed, Shanghai, China.
  • Wang M; Harbour BioMed, Shanghai, China.
  • Chen S; Harbour BioMed, Shanghai, China.
  • Ousler GW; Ora Inc, Andover, MA, USA.
  • Chen X; Harbour BioMed, Shanghai, China.
  • Xie L; Qingdao Eye Hospital of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University, Qingdao, China. lixin_xie@hotmail.com.
Int Ophthalmol ; 42(8): 2459-2472, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35192105
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes do Olho Seco / Fator de Necrose Tumoral alfa Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Int Ophthalmol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes do Olho Seco / Fator de Necrose Tumoral alfa Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Int Ophthalmol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China